The US FDA may limit Covid-19 boosters to high-risk groups only, citing lack of efficacy in healthy individuals. Meanwhile, ...

The framework the new FDA leaders laid out on Tuesday raised small and big questions about the regulatory process, vaccine ...

The hearing was supposed to focus on the Trump administration’s 2026 budget request, but instead covered a wide range of ...

The FDA may limit annual COVID-19 boosters to high-risk groups unless clinical trials prove benefits for healthy adults under 65. Pfizer is reviewing the plan, while officials call for more evidence ...

This week, two new leaders at the US Food and Drug Administration announced plans to limit access to covid vaccines, arguing ...

The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans, a move that may limit ...

FDA advisory panel to vote on COVID-19 vaccine strains for 2025-2026 campaign amid uncertainty over dominant variants.

Seven weeks into his job as FDA commissioner, Marty Makary, MD, MPH, held his own answering a barrage of sometimes ...

The US Food and Drug Administration may limit Covid-19 boosters shots to high-risk groups from 2025; Pfizer reviewing proposal as agency seeks new trials, clearer risk labels for younger males ...

US regulators will no longer approve Covid booster shots for healthy adults and children without new studies, adding a costly ...

Despite an explanation of the new strategy published Tuesday from FDA Commissioner Marty Makary and Vinay Prasad, who ...

Under the new approach, updated Covid-19 vaccines are likely to be available this autumn only for people aged 65 and older, ...